Therapeutic drug monitoring of selumetinib in pediatrics: a combined LC-MS/MS and LC-HRMS approach

Therapeutic drug monitoring of selumetinib in pediatrics: a combined LC-MS/MS and LC-HRMS approach

Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of plexiform neurofibromas (PNs), benign yet potentially debilitating tumors with limited treatment options. Selumetinib, a selective MEK1/2 inhibitor, has emerged as a targeted therapy for symptomatic, inoperable...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessia Cafaro, Andrea Santangelo, Sebastiano Barco, Corinna Corsini, Roberto Bandettini, Pasquale Striano, Maria Cristina Diana, Giuliana Cangemi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Pharmacology
Subjects:
neurofibromatosis type 1
selumetinib
therapeutic drug monitoring
LC-MS/MS
metabolites
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1649335/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items